Webinar: Prof. Thomas Jaki – Platform trials: only suitable for a pandemic?

Click here to register

The COVID-19 pandemic has create many challenges for clinical trials. On the one hand running studies have been severely affected while on the other hand many challenges arose for trial looking at treatments for COVID. Platform trials have become a particularly popular solution to evaluate treatment for COVID. In this talk, Prof. Jaki will discuss his experiences with early COVID trials in China and how they influenced the design of the adaptive platform trial RECOVERY. He will also discuss some of the statistical aspect of its design and reflect on some of the open questions to make platform trials even more broadly applicable.

Speaker:

Prof. Thomas Jaki is the Professor of Computational Statistics at the University of Regensburg and MRC Professor of Statistics and Programme Leader in the Efficient Study Design theme at the MRC Biostatistics Unit. Prof. Jaki’s work focuses on developing and evaluating novel statistical methods for clinical studies. These methods are adapted for specific applications to ensure they can be used in the pharmaceutical industry and also in public sector research institutions. His current research focuses on model-based dose-finding trials as well as Master protocols.